Does the media favor QGEN or RAPP?

In the previous week, Qiagen had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 6 mentions for Qiagen and 4 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.58 beat Qiagen's score of -0.43 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Qiagen 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rapport Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, PCVX or RAPP?

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaxcyte N/A N/A -$766.63M -$6.88 N/A Rapport Therapeutics N/A N/A -$111.48M -$2.60 N/A

Is PCVX or RAPP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Vaxcyte's return on equity. Company Net Margins Return on Equity Return on Assets Vaxcyte N/A -32.51% -29.51% Rapport Therapeutics N/A -24.78% -23.44%

Does the media refer more to PCVX or RAPP?

In the previous week, Vaxcyte had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 5 mentions for Vaxcyte and 4 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.58 beat Vaxcyte's score of 0.21 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rapport Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, IMVT or RAPP?

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.78 N/A Rapport Therapeutics N/A N/A -$111.48M -$2.60 N/A

Is IMVT or RAPP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Rapport Therapeutics N/A -24.78% -23.44%

Does the media refer more to IMVT or RAPP?

In the previous week, Immunovant had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 6 mentions for Immunovant and 4 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.58 beat Immunovant's score of 0.43 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Rapport Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LNTH or RAPP?

In the previous week, Lantheus and Lantheus both had 4 articles in the media. Rapport Therapeutics' average media sentiment score of 0.58 beat Lantheus' score of 0.54 indicating that Rapport Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KYMR or RAPP?

In the previous week, Kymera Therapeutics and Kymera Therapeutics both had 4 articles in the media. Kymera Therapeutics' average media sentiment score of 1.39 beat Rapport Therapeutics' score of 0.58 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rapport Therapeutics (RAPP) Competitors

$37.49 +0.49 (+1.32%)

Closing price 04:00 PM Eastern

Extended Trading

$37.50 +0.01 (+0.03%)

As of 04:36 PM Eastern

Compare

RAPP vs. QGEN, PCVX, IMVT, LNTH, and KYMR

Should you buy Rapport Therapeutics stock or one of its competitors? MarketBeat compares Rapport Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rapport Therapeutics include Qiagen (QGEN), Vaxcyte (PCVX), Immunovant (IMVT), Lantheus (LNTH), and Kymera Therapeutics (KYMR). These companies are all part of the "pharmaceutical products" industry.

How does Rapport Therapeutics compare to Qiagen?

Qiagen (NYSE:QGEN) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

In the previous week, Qiagen had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 6 mentions for Qiagen and 4 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.58 beat Qiagen's score of -0.43 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Qiagen	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rapport Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Qiagen has a net margin of 19.16% compared to Rapport Therapeutics' net margin of 0.00%. Qiagen's return on equity of 14.40% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Qiagen	19.16%	14.40%	8.40%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Qiagen presently has a consensus price target of $44.98, indicating a potential upside of 19.92%. Rapport Therapeutics has a consensus price target of $58.83, indicating a potential upside of 56.93%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rapport Therapeutics is more favorable than Qiagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Qiagen	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Qiagen has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Qiagen	$2.09B	3.70	$424.88M	$1.91	19.64
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Qiagen has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Qiagen beats Rapport Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Rapport Therapeutics compare to Vaxcyte?

Vaxcyte (NASDAQ:PCVX) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

In the previous week, Vaxcyte had 1 more articles in the media than Rapport Therapeutics. MarketBeat recorded 5 mentions for Vaxcyte and 4 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.58 beat Vaxcyte's score of 0.21 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaxcyte	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rapport Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vaxcyte currently has a consensus price target of $86.00, suggesting a potential upside of 76.37%. Rapport Therapeutics has a consensus price target of $58.83, suggesting a potential upside of 56.93%. Given Vaxcyte's higher possible upside, equities research analysts clearly believe Vaxcyte is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Rapport Therapeutics' return on equity of -24.78% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaxcyte	N/A	-32.51%	-29.51%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Vaxcyte has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

96.8% of Vaxcyte shares are owned by institutional investors. 3.3% of Vaxcyte shares are owned by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Rapport Therapeutics beats Vaxcyte on 9 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

47.1% of Immunovant shares are held by institutional investors. 1.8% of Immunovant shares are held by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rapport Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Immunovant presently has a consensus price target of $37.33, indicating a potential upside of 14.27%. Rapport Therapeutics has a consensus price target of $58.83, indicating a potential upside of 56.93%. Given Rapport Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rapport Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Immunovant had 2 more articles in the media than Rapport Therapeutics. MarketBeat recorded 6 mentions for Immunovant and 4 mentions for Rapport Therapeutics. Rapport Therapeutics' average media sentiment score of 0.58 beat Immunovant's score of 0.43 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rapport Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rapport Therapeutics' return on equity of -24.78% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Summary

Rapport Therapeutics beats Immunovant on 11 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

99.1% of Lantheus shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 12.5% of Rapport Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lantheus presently has a consensus price target of $101.86, suggesting a potential downside of 0.94%. Rapport Therapeutics has a consensus price target of $58.83, suggesting a potential upside of 56.93%. Given Rapport Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rapport Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Lantheus and Lantheus both had 4 articles in the media. Rapport Therapeutics' average media sentiment score of 0.58 beat Lantheus' score of 0.54 indicating that Rapport Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.34	$233.56M	$4.15	24.78
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Lantheus has a net margin of 18.05% compared to Rapport Therapeutics' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Summary

Lantheus beats Rapport Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Rapport Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Rapport Therapeutics (NASDAQ:RAPP) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Rapport Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Rapport Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Rapport Therapeutics	N/A	-24.78%	-23.44%

Kymera Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Kymera Therapeutics currently has a consensus target price of $118.10, suggesting a potential upside of 58.28%. Rapport Therapeutics has a consensus target price of $58.83, suggesting a potential upside of 56.93%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.95
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Rapport Therapeutics has lower revenue, but higher earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	156.53	-$311.35M	-$3.57	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

In the previous week, Kymera Therapeutics and Kymera Therapeutics both had 4 articles in the media. Kymera Therapeutics' average media sentiment score of 1.39 beat Rapport Therapeutics' score of 0.58 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kymera Therapeutics beats Rapport Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Rapport Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RAPP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RAPP vs. The Competition

Export

Metric	Rapport Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.79B	$3.35B	$6.44B	$12.47B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-14.42	18.72	23.87	24.40
Price / Sales	N/A	320.32	521.86	117.01
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	3.69	6.80	9.99	6.73
Net Income	-$111.48M	$24.09M	$3.56B	$337.03M
7 Day Performance	-5.06%	-2.48%	-0.87%	0.11%
1 Month Performance	N/A	N/A	N/A	-1.70%
1 Year Performance	187.06%	48.95%	28.77%	34.24%

Rapport Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RAPP Rapport Therapeutics	3.3422 of 5 stars	$37.49 +1.3%	$58.83 +56.9%	+202.3%	$1.79B	N/A	N/A	N/A	Analyst Forecast
QGEN Qiagen	3.9843 of 5 stars	$35.47 +0.9%	$44.98 +26.8%	-23.5%	$7.31B	$2.09B	18.52	5,654
PCVX Vaxcyte	2.8058 of 5 stars	$50.11 +5.9%	$86.00 +71.6%	+35.4%	$7.24B	N/A	N/A	160	Insider Trade
IMVT Immunovant	2.1313 of 5 stars	$33.83 -0.9%	$37.33 +10.4%	+101.7%	$6.95B	N/A	N/A	120
LNTH Lantheus	2.068 of 5 stars	$100.06 -2.9%	$99.71 -0.3%	+29.0%	$6.71B	$1.55B	24.11	1,193

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RAPP) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rapport Therapeutics (RAPP) Competitors

RAPP vs. QGEN, PCVX, IMVT, LNTH, and KYMR

How does Rapport Therapeutics compare to Qiagen?

Summary

How does Rapport Therapeutics compare to Vaxcyte?

Summary

How does Rapport Therapeutics compare to Immunovant?

Summary

How does Rapport Therapeutics compare to Lantheus?

Summary

How does Rapport Therapeutics compare to Kymera Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rapport Therapeutics (RAPP) Competitors

RAPP vs. QGEN, PCVX, IMVT, LNTH, and KYMR

How does Rapport Therapeutics compare to Qiagen?

Does the media favor QGEN or RAPP?

Is QGEN or RAPP more profitable?

Do analysts rate QGEN or RAPP?

Which has preferable valuation & earnings, QGEN or RAPP?

Which has more risk and volatility, QGEN or RAPP?

Do insiders and institutionals believe in QGEN or RAPP?

Summary

How does Rapport Therapeutics compare to Vaxcyte?

Which has higher earnings and valuation, PCVX or RAPP?

Does the media refer more to PCVX or RAPP?

Do analysts recommend PCVX or RAPP?

Is PCVX or RAPP more profitable?

Which has more risk and volatility, PCVX or RAPP?

Do insiders and institutionals hold more shares of PCVX or RAPP?

Summary

How does Rapport Therapeutics compare to Immunovant?

Which has more risk & volatility, IMVT or RAPP?

Do institutionals and insiders believe in IMVT or RAPP?

Which has preferable earnings and valuation, IMVT or RAPP?

Do analysts recommend IMVT or RAPP?

Does the media refer more to IMVT or RAPP?

Is IMVT or RAPP more profitable?

Summary

How does Rapport Therapeutics compare to Lantheus?

Do institutionals & insiders have more ownership in LNTH or RAPP?

Do analysts rate LNTH or RAPP?

Does the media refer more to LNTH or RAPP?

Which has stronger valuation and earnings, LNTH or RAPP?

Which has more risk & volatility, LNTH or RAPP?

Is LNTH or RAPP more profitable?

Summary

How does Rapport Therapeutics compare to Kymera Therapeutics?

Is KYMR or RAPP more profitable?

Which has more volatility and risk, KYMR or RAPP?

Do analysts rate KYMR or RAPP?

Which has better earnings & valuation, KYMR or RAPP?

Does the media refer more to KYMR or RAPP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RAPP vs. The Competition

Rapport Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools